secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-05-14T11:32:05+00:00
Accession:  0001193125-26-222808
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q1 revenue $35.1M, net loss $22.4M; Phase 3 endometrial trial enrollment complete
--------------------------------------------------------------------------------

- U.S. XPOVIO net product revenue $29.2M (up from $21.1M YoY) on lower gross-to-net adjustments.
- Net loss $22.4M ($1.02 basic loss per share) vs $23.5M loss in Q1 2025.
- Cash $91.2M as of Mar 31, 2026; expects liquidity to fund operations into late Q3 2026.
- Completed Phase 3 XPORT-EC-042 enrollment in endometrial cancer; topline data expected mid-2026.
- Phase 3 SENTRY myelofibrosis results accepted for late-breaking oral at ASCO on June 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526222808/0001193125-26-222808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526222808/kpti-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-222808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer